-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gemogenovatucel-T in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gemogenovatucel-T in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gemogenovatucel-T in Non-Small Cell Lung Cancer Drug Details: Gemogenovatucel-T (Vigil)...
-
Product Insights
Ewing Sarcoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Ewing Sarcoma Clinical Trial Report Overview A total of 434 Ewing Sarcoma clinical trials were conducted as of February 2024. The Ewing Sarcoma clinical trial report provides a comprehensive understanding of the Ewing Sarcoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North America ·       ...
-
Product Insights
Inclusion Body Myositis (IBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Inclusion Body Myositis (IBM) - Drugs In Development, 2023’, provides an overview of the Inclusion Body Myositis (IBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Primitive Neuroectodermal Tumor (PNET) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primitive Neuroectodermal Tumor (PNET) - Drugs In Development, 2023’, provides an overview of the Primitive Neuroectodermal Tumor (PNET) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primitive Neuroectodermal Tumor (PNET), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hereditary Inclusion Body Myopathy (h-IBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hereditary Inclusion Body Myopathy (h-IBM) - Drugs In Development, 2023’, provides an overview of the Hereditary Inclusion Body Myopathy (h-IBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hereditary Inclusion Body Myopathy (h-IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Ewing Sarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ewing Sarcoma - Drugs In Development, 2023’, provides an overview of the Ewing Sarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma in Ewing Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RNAi Gene Therapy to...